Neuberger Berman Group LLC Enlivex Therapeutics Ltd. Transaction History
Neuberger Berman Group LLC
- $114 Billion
- Q1 2025
A detailed history of Neuberger Berman Group LLC transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Neuberger Berman Group LLC holds 14,000 shares of ENLV stock, worth $20,020. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,000Holding current value
$20,020% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ENLV
# of Institutions
29Shares Held
3.17MCall Options Held
44.3KPut Options Held
7.1K-
Armistice Capital, LLC New York, NY1.78MShares$2.55 Million0.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny669KShares$956,6810.0% of portfolio
-
Morgan Stanley New York, NY231KShares$329,8790.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny181KShares$259,2430.0% of portfolio
-
Jane Street Group, LLC New York, NY80.8KShares$115,4850.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $26.3M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...